Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Published byΟφιούχος Φραγκούδης Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)"— Presentation transcript:

1 Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)
Figure 3 | Putative actions of glucagon-like peptide 1 (GLP-1). The best elucidated physiological roles of GLP-1 are those related to pancreatic islet cell function. However, GLP-1 and GLP-1 receptor agonists also have pleiotropic effects on various other tissues and organs, with various potential physiological, pathophysiological and pharmacological implications. VLDL, very low density lipoprotein. Muskiet, M. H. A. et al. (2017) GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)"

Similar presentations

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 2 Pathophysiology of hyperglycaemia in T2DM

Figure 2 Pathophysiology of hyperglycaemia in T2DM
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Stuart A. Ross, MB CHB, FRACP, FRCP(C) 

Stuart A. Ross, MB CHB, FRACP, FRCP(C) 
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 6 Differences in glycaemic control with the study drug

Figure 6 Differences in glycaemic control with the study drug
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Expression of coagulation protease receptors in renal cells
Figure 3 Angiotensin signalling in adiporenal crosstalk

Figure 3 Angiotensin signalling in adiporenal crosstalk
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Physiological changes in the renal system in pregnancy
Figure 1 Role of the kidney in glucose homeostasis

Figure 1 Role of the kidney in glucose homeostasis
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Similar presentations

Ads by Google